EUVIMEDEUVIMED entdecken
Open Access

Multiomic Mendelian Randomization Study Investigating the Impact of PCSK9 and HMGCR Inhibition on Type 2 Diabetes Across Five Populations

Daniel B Rosoff, Josephin Wagner, Jeesun Jung, Pal Pacher, Constantinos Christodoulides iD, George Davey Smith, David Ray, Falk W Lohoff iD

Diabetes · 01.01.2025 · 74 (1) · 120-130

DOI: 10.2337/db24-0451 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Diabetes, online erschienen am 17.10.2024. Verfasst von Daniel B Rosoff und 7 weiteren Autor:innen. Beteiligte Einrichtung: Section on Clinical Genomics and Experimental Therapeutics, National Institute on Alcohol Abuse and Alcoholism, National Institutes of Health, Bethes…. Hauptthemen laut MEDLINE: Diabetes Mellitus, Type 2, Mendelian Randomization Analysis, Hydroxymethylglutaryl CoA Reductases, Proprotein Convertase 9. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 53 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: Intramural NIH HHS, CLC NIH HHS, Clinical Center.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The prevalence of type 2 diabetes (T2D) varies among populations of different races/ethnicities. The influence of genetically proxied LDL cholesterol lowering through proprotein convertase subtilisin/kexin 9 (PCSK9) and HMG-CoA reductase (HMGCR) on T2D in non-European populations is not well established. A drug target Mendelian randomization approach was used to assess the effects of PCSK9 and HMGCR inhibition on T2D risk and glycemic traits in five populations: East Asian (EAS), South Asian (SAS), Hispanic (HISP), African (AFR), and Europe (EUR). Our study did not find relationships between genetically proxied PCSK9 inhibition and T2D risk in the EAS (odds ratio [OR] 1.02; 95% CI 0.95–1.10), SAS (1.05; 0.97–1.14), HISP (1.03; 0.94–1.12), or EUR population (1.04; 0.98–1.11). However, in the AFR population, primary analyses suggested an increased risk of T2D resulting from PCSK9 inhibition (OR 1.53; 95% CI 1.058–2.22; P = 0.024), although this was not supported in sensitivity analyses. Genetically proxied HMGCR inhibition was associated with an increased risk of T2D in SAS (OR 1.44; 95% CI 1.30–1.61; P = 9.8 × 10−12), EAS (1.36; 1.22–1.51; P = 4.2 × 10−10), and EUR populations (1.52; 1.21–1.90; P = 3.3 × 10−4). These results were consistent across various sensitivity analyses, including colocalization, indicating a robust finding. The findings indicate a neutral impact of long-term PCSK9 inhibition on T2D and glycemic markers in most non-EUR populations, with a potential increased risk in AFR cohorts. By contrast, HMGCR inhibition increased the risk of T2D in SAS, EAS, and EUR cohorts, underscoring the need to consider diversity in genetic research on metabolic diseases. Article Highlights

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Diabetes Mellitus, Type 2Mendelian Randomization AnalysisHydroxymethylglutaryl CoA ReductasesProprotein Convertase 9HumansPolymorphism, Single NucleotideEuropeMaleFemaleCholesterol, LDLHydroxymethylglutaryl-CoA Reductase Inhibitors

Substanzen

Hydroxymethylglutaryl CoA ReductasesProprotein Convertase 9HMGCR protein, humanPCSK9 protein, humanCholesterol, LDLHydroxymethylglutaryl-CoA Reductase Inhibitors

Autor:innen und Institutionen

  • Section on Clinical Genomics and Experimental Therapeutics, National Institute on Alcohol Abuse and Alcoholism, National Institutes of Health, Bethesda, MD.
  • Oxford Centre for Diabetes, Endocrinology and Metabolism, Radcliffe Department of Medicine, University of Oxford, Oxford, U.K.
  • Medical Research Council Integrative Epidemiology Unit, University of Bristol, Bristol, U.K.
  • Laboratory of Cardiovascular Physiology and Tissue Injury, National Institute on Alcohol Abuse and Alcoholism, National Institutes of Health, Bethesda, MD.
  • National Institute for Health and Care Research Oxford Biomedical Research Centre, John Radcliffe Hospital, Oxford, U.K.

ORCID-Profile: Constantinos Christodoulides, Falk W Lohoff

Förderung

  • Intramural NIH HHS
  • CLC NIH HHS
  • Clinical Center

Zitieren

APA

Rosoff, D. B., Wagner, J., Jung, J., Pacher, P., Christodoulides, C., Davey Smith, G., Ray, D., & Lohoff, F. W. (2025). Multiomic Mendelian Randomization Study Investigating the Impact of PCSK9 and HMGCR Inhibition on Type 2 Diabetes Across Five Populations. Diabetes, 74(1), 120-130. https://doi.org/10.2337/db24-0451

Vancouver

Rosoff DB, Wagner J, Jung J, Pacher P, Christodoulides C, Davey Smith G, et al. Multiomic Mendelian Randomization Study Investigating the Impact of PCSK9 and HMGCR Inhibition on Type 2 Diabetes Across Five Populations. Diabetes. 2025;74(1):120-130. doi:10.2337/db24-0451

BibTeX
@article{Rosoff2025,
  author = {Rosoff, Daniel B and Wagner, Josephin and Jung, Jeesun and Pacher, Pal and Christodoulides, Constantinos and Davey Smith, George and Ray, David and Lohoff, Falk W},
  title = {Multiomic Mendelian Randomization Study Investigating the Impact of PCSK9 and HMGCR Inhibition on Type 2 Diabetes Across Five Populations},
  journal = {Diabetes},
  year = {2025},
  volume = {74},
  number = {1},
  pages = {120--130},
  doi = {10.2337/db24-0451}
}
Kostenlos starten →